TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37984940
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II as a second-line vasopressor infusion during liver transplantation.
Study: 37984940
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo as the second-line vasopressor infusion during liver transplantation.
Study: 37985359
Drug: Ibrutinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (oral Bruton tyrosine kinase inhibitor), lenalidomide (15 mg days 1-21 cycle 1; 20 mg cycles 2-12), and rituximab (375 mg/m2) for 12 cycles of 28 days each.
Study: 37985386
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with immunotherapy (NACI)
Study: 37985697
Drug: 2-mg CPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg CPC buccal tablet
Study: 37985968
Drug: eptinezumab 100
Normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptinezumab 100 mg (continuation from placebo)
Study: 37985968
Drug: eptinezumab 300
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: eptinezumab 300 mg (continuation from placebo)
Study: 37985994
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence
Study: 37985994
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence in MASLD(+) patients
Study: 37985994
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence in MASLD(-) patients
Study: 37986155
Drug: ECOHIS (Early
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECOHIS (Early Childhood Oral Health Impact Scale)
Study: 37986155
Drug: Child-OIDP (Child
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-OIDP (Child Oral Impact on Daily Performance)
Study: 37986556
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg i.v. bi-weekly for up to 12 months (Part 1)
Study: 37986556
Drug: Sequential addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential addition of ipilimumab 1 mg/kg three-weekly for four doses to nivolumab (Part 2)
Study: 37986836
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and Endocrine therapy
Study: 38468320
Drug: Novel 4-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel 4-month treatment regimens
Study: 37986911
Drug: GD2BATs (anti-CD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GD2BATs (anti-CD3 x anti-GD2 bispecific antibody armed T cells)
Study: 37987108
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor monotherapy after three months of dual antiplatelet therapy (DAPT)
Study: 38649069
Drug: Heparinase I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinase I treatment
Study: 37988294
Drug: Stereotactic arrhythmia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic arrhythmia radioablation (STAR) with a total dose of 25 Gy (single fraction) delivered in 3 min
Study: 37988402
Drug: Daily intra-muscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intra-muscular paromomycin (20mg/kg, 14 days) plus oral miltefosine (allometric dose, 42 days) - PM/MF
Study: 37988402
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (total dose of 20mg/kg, administered in four injections in week one) and oral miltefosine (allometric dose, 28 days) - LAmB/MF
Study: 37988413
Drug: PIVKA-II ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIVKA-II ≤ 240 mAU/ml
Study: 37988413
Drug: PIVKA-II >
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIVKA-II > 240 mAU/ml
Study: 37988638
Drug: Induction pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction pembrolizumab (200 mg, once every 21 days) followed by risk-adapted thoracic radiotherapy (55 Gy for tumors or lymph nodes >20 cc, 48 Gy for smaller lesions) and consolidation pembrolizumab for 1 year.
Study: 37988638
Drug: Induction pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction pembrolizumab (200 mg, once every 21 days)
Study: 37989142
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (25 micrograms every 3 hours for up to five doses)
Study: 37989142
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 micrograms every 4 hours for up to two doses)
Study: 37989361
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention integrated with personal medical nutrition therapy
Study: 37989370
Drug: Cervical length
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical length measurement and fetal fibronectin test (not specified if used in combination)
Study: 37989381
Drug: Single-antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-antiplatelet therapy (SAPT) with aspirin 75-100 mg for 6 months
Study: 37989381
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) with warfarin, therapeutic international normalised ratio at 1.8-2.5 for 6 months
Study: 37989482
Drug: Ombrabulin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (35 mg/m²) in combination with paclitaxel and carboplatin
Study: 37989482
Drug: Ombrabulin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (25 mg/m² or 30 mg/m²) in combination with paclitaxel and carboplatin
Study: 37989943
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid solution (Plasma-Lyte)
Study: 37990173
Drug: Light hypnosis
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light hypnosis (non-drug intervention) in healthy controls (CTRL)
Study: 37990224
Drug: Intra-mucosal injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-mucosal injection of vitamin C (L-Ascorbic acid 1000 mg/5 ml)
Study: 37990252
Drug: Normal 2
Normalized name: LANCET,UNISTIK CZT NORMAL 23G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal 2 hours of weekly physical education (Control schools n=9)
Study: 37991178
Drug: Personalized Conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized Conservative Treatment (PCT)
Study: 37991639
Drug: ABY-025 (Affibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABY-025 (Affibody molecule)
Study: 38884880
Drug: Medication optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication optimization intervention
Study: 37991657
Drug: Medication optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication optimization intervention (non-long stayers)
Study: 37991657
Drug: Medication optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication optimization intervention (long stayers)
Study: 37991745
Drug: Abbreviated DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated DAPT (immediate DAPT discontinuation, followed by single APT for ≥6 months)
Study: 37991778
Drug: Neoadjuvant carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant carboplatin (AUC 6) and docetaxel (75 mg/m2) plus pembrolizumab (200 mg) every 21 days for 6 cycles
Study: 37991835
Drug: CO monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO monitoring for guidance of intraoperative fluid therapy and low-dose dobutamine infusion (2.5 μg/kg/hr) for up to 4 hours postoperatively.
Study: 37991835
Drug: CO-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO-directed fluid therapy with low-dose dobutamine infusion.
Study: 37991835
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (current practice without CO monitoring and dobutamine infusion).
Study: 37992000
Drug: SIIV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIIV administered alone
Study: 37992000
Drug: RSVpreF administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF administered alone
Study: 37992063
Drug: Coded card
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coded card containing treatment details
Study: 37992063
Drug: Alternative drug
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative drug packaging to conceal drug identity
Study: 37992183
Drug: Novavax protein-based
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novavax protein-based COVID-19 vaccine (NVX-CoV2373)
Study: 37992203
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment initiation
Study: 37992970
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 1.0 g⋅kg
Study: 37992970
Drug: Protein intakes
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intakes ranging from 0.6 to 1.5 g⋅kg
Study: 37993033
Drug: Mirikizumab 1000
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 1000 mg at week 12
Study: 37993033
Drug: Mirikizumab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab (any dose) at 1 year
Study: 37993033
Drug: Mirikizumab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab (any dose) at 1 year based on week 12 response
Study: 37993062
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × CC
Study: 37993149
Drug: Niraparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (200 or 300 mg daily in a 3-weekly cycle)
Study: 37993168
Drug: Robotic device
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic device (ALBA) with regular treatment
Study: 37993889
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg levetiracetam twice daily for 14 days
Study: 37994553
Drug: Prasugrel (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (3.75 mg/day) monotherapy
Study: 37994553
Drug: DAPT with
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT with aspirin (81-100 mg/day) and prasugrel (3.75 mg/day)
Study: 37994989
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 1 g/day for 10 weeks
Study: 37995070
Drug: Molnupiravir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir (800 mg every 12 hours for 5 days)
Study: 37996071
Drug: Variant-specific IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variant-specific IgA antibody response at 1 month after booster vaccination
Study: 37996236
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) with screening but without consequences (phase I, main comparator)
Study: 37996236
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) without screening for distress (phase 0)
Study: 37996238
Drug: Extended ECG
Normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended ECG monitoring (14+14 days of continuous ECG monitoring 3 months apart using an ECG patch device)
Study: 37996653
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ISO with visceral adipose tissue (VAT) and other NAFLD-related variables
Study: 37996787
Drug: Dexmedetomidine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0 µg/kg) in Group A-Y
Study: 37996787
Drug: Dexmedetomidine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0 µg/kg) in Group A-O
Study: 37996787
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 µg/kg) in Group B
Study: 37996787
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg/kg) in Group C
Study: 37996787
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 µg/kg)
Study: 37996787
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg/kg)
Study: 37997387
Drug: Brief dialectical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief dialectical behavior therapy (DBT)
Study: 37997387
Drug: Pre-treatment cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment cognitive performance
Study: 37997800
Drug: Angptl7 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Angptl7 treatment
Study: 37999672
Drug: Transcutaneous Vagus
Normalized name: Sus scrofa vagus nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous Vagus Nerve Stimulation (tVNS) at 20 Hz, 1 mA below discomfort threshold, delivered for 1 hour daily over 2 months.
Study: 37999854
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab
Study: 37999854
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus placebo followed by adjuvant placebo
Study: 37999936
Drug: PROXY (8-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROXY (8-week psychological internet-delivered treatment)
Study: 37999939
Drug: Perampanel (PER)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (PER) 4 mg per day
Study: 37999939
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000 mg per day
Study: 37999982
Drug: Anticholinergic burden
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic burden assessed using the Anticholinergic Cognitive Burden scale (ACB) and Drug Burden Index (DBI) scale
Study: 38000343
Drug: Low-intensity chemotherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity chemotherapy (n=53), Intensive chemotherapy (n=6)
Study: 38001474
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1000 mg fish oil, 13% EPA, 9% DHA) with glimepiride 3 mg
Study: 38001474
Drug: Placebo (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn oil and linoleic acid) with glimepiride 3 mg
Study: 38002635
Drug: Twice-weekly thirty-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly thirty-minute exercise intervention
Study: 38004228
Drug: Carnosine 2
Normalized name: ASCORBIC ACID 200 mg / Vitamin D 20 ug / FOLIC ACID 1667 ug / CYANOCOBALAMIN 6 ug / CALCIUM CITRATE 40 mg / IRON PROTEIN SUCCINYLATE 3.6 mg / MAGNESIUM GLYCINATE 8.5 mg / MAGNESIUM OXIDE 60.3 mg / ZINC 8 mg / POLAPREZINC 37.5 mg / CARNOSINE 28 mg ORAL CAPSULE [Remedient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine 2 g/day
Study: 38004546
Drug: Standard berberine
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard berberine formulation
Study: 38006892
Drug: VV116 (0·6
Approvals — FDA: no, EMA: no, PMDA: no
Description: VV116 (0·6 g every 12 h on day 1 and 0·3 g every 12 h on days 2-5)
Study: 38006908
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy targeting systolic BP <130 mm Hg
Study: 38006908
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy targeting systolic BP <140 mm Hg
Study: 38006972
Drug: Berotralstat 150
Normalized name: berotralstat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotralstat 150 mg once-daily monotherapy
Study: 38007586
Drug: Bosutinib (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib (starting dose: 500 mg/day)
Study: 38007646
Drug: Gustatory evoked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gustatory evoked potentials (GEPs) in response to sucrose solution
Study: 38007646
Drug: Cognitive assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive assessments and hormone levels (ghrelin, leptin, insulin, serotonin)
Study: 38008031
Drug: Belzutifan 120
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan 120 mg orally once daily until disease progression, unacceptable toxicity, or patient withdrawal.
Study: 38008033
Drug: Consolidating high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidating high-dose therapy and autologous hematopoietic stem cell transplantation (HDT-ASCT) in partial response (PR) or better
Study: 38008305
Drug: Oral levonorgestrel
Normalized name: levonorgestrel Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levonorgestrel emergency contraception with same-day etonogestrel implant insertion
Study: 38009241
Drug: donidalorsen 80
Normalized name: Donidalorsen
DrugBank: Donidalorsen (DB18751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: donidalorsen 80 mg subcutaneously every 4 weeks (Q4W)
Study: 38009241
Drug: donidalorsen 80
Normalized name: Donidalorsen
DrugBank: Donidalorsen (DB18751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: donidalorsen 80 mg every 8 weeks (Q8W)
Study: 38009662
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (tremelimumab plus durvalumab)
Study: 38009662
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (tremelimumab followed by durvalumab)
Study: 38009966
Drug: Active (anodal)
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active (anodal) transcranial direct current stimulation (tDCS) targeting the mPFC during exposure therapy
Study: 38009966
Drug: Sham transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transcranial direct current stimulation (tDCS) during exposure therapy
Study: 38009966
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy (giving speeches to audiences in virtual reality)
Study: 38010260
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg once daily (q.d.)
Study: 38010260
Drug: Comparator EGFR-TKIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator EGFR-TKIs (gefitinib 250 mg q.d. or erlotinib 150 mg q.d.)
Study: 38010606
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ropeginterferon alfa-2b at 250 μg plus standard of care (SOC)
Study: 38010758
Drug: Randomly chosen
Normalized name: LANCET,CHOSEN DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly chosen sessions from the same treatment phase
Study: 38011129
Drug: Preloaded combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preloaded combination nicotine replacement therapy (NRT)
Study: 38011129
Drug: Fast-acting nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting nicotine replacement therapy (NRT) alone
Study: 38011131
Drug: [68Ga]FAPI-46 PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: [68Ga]FAPI-46 PET after neoadjuvant therapy (NAT)
Study: 38011235
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 µg BID subcutaneous injection) for 5 days or until hospital discharge.
Study: 38011235
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 µg BID subcutaneous injection).
Study: 38011688
Drug: Heated intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated intravenous (IV) fluids
Study: 38011688
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of forced-air warming and heated IV and irrigation fluids
Study: 38011750
Drug: Acceptance-Commitment Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-Commitment Therapy
Study: 38011968
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg) and Cetuximab (500, 400 or 300 mg/m2)
Study: 38011967
Drug: TM+Continued (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM+Continued (monthly text messages)
Study: 38011967
Drug: TM+ &
Normalized name: I do not have enough information to determine the full generic name for the drug abbreviation "TM+ &" based solely on the provided information. Drug abbreviations can vary and may not have a clear or standardized mapping to their full generic names. Without more context about the specific drug or clinical trial data, I cannot confidently provide the full generic name. The best I can suggest is to refer to the original clinical trial documentation or consult a medical reference source for more details about this particular drug abbreviation.
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM+ & MAPS (monthly text messages, plus up to 2 MAPS calls)
Study: 38011984
Drug: Nebulised 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised 3% hypertonic saline (5 mL, three times a day)
Study: 38011984
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (5 mL, three times a day)